A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain

This study is for patients with advanced bile duct or pancreatic cancer who are experiencing pain from their disease. The purpose of this research is to learn about the effects of combining a standard pain relief treatment (Celiac Plexus Block) with standard first-line cancer drugs. Patients in this study will receive the Celiac Plexus Block procedure, which is intended to reduce pain, and will then begin their standard cancer medication regimen. Researchers will observe and compare how well this combined approach works to control pain and the cancer itself, and will monitor for any side effects. Participation in this study involves being followed by the research team for up to 2 years to track health outcomes. The goal is to see if starting cancer treatment together with this specialized pain management technique is more helpful for patients compared to what is already known about the standard treatments alone.

NCT Number	NCT07326137
Lead Sponsor	Tongji Hospital
Conditions	Advanced Biliary Tract Cancer(BTC), Advanced Pancreatic Cancers, Cancer-related Pain
Enrollment	103 participants
Start Date	2025-12-26
Primary Completion	2028-06-26 (estimated)
Study Completion	2028-12-26 (estimated)
Updated on ClinicalTrials.gov	2026-02-11